Fund overview

This global health care fund seeks consistent returns by investing in companies addressing unmet medical needs or making the health care system more efficient. We balance the portfolio across pharmaceuticals, biotechnology and services/devices sub-sectors in an effort to achieve consistent outperformance of the benchmark and peers.


Why consider the fund?
Finding growth in health care

The long-term drivers of growth in the health care sector include powerful global demographic trends rapidly accelerating and compounding innovation and the globalization of health care. Within this environment, the Fund seeks to invest in growth companies that are addressing unmet medical needs or making the health care system more efficient and affordable.

Dedicated sector experts

Our dedicated team of analysts has more than 100 years of combined experience investing in health care companies. In this complex and rapidly growing sector, we believe it is critical to have an experienced team that seeks to understand both the science and the business of the companies in which they invest.

Deep and disciplined

We believe the combination of deep fundamental research and disciplined portfolio construction will lead to consistently strong results relative to both the health care sector and the broader equity market. The fund is balanced across the subsectors of health care and diversified across market-cap segments and geographies.


Andy Acker Portrait

Andy Acker, CFA

Fund Manager since 2007

Industry since 1996

Ethan Lovell Portrait

Ethan Lovell

Fund Manager since 2016

Industry since 1994

Effective 12th January 2016 Ethan Lovell became Co-Portfolio Manager of the Janus Global Life Sciences Fund and affiliated accounts, joining Andy Acker, who was previously sole manager of the Fund.

Past performance is no guarantee of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. This is not a solicitation for the sale of shares and nothing herein is intended to amount to investment advice.